Gyre Therapeutics (NASDAQ:GYRE) Posts Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) released its earnings results on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06), FiscalAI reports. The firm had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $26.49 million. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%.

Gyre Therapeutics Trading Up 0.1%

NASDAQ GYRE traded up $0.01 on Thursday, reaching $6.66. 8,185 shares of the company were exchanged, compared to its average volume of 87,320. The business’s fifty day moving average price is $6.46 and its 200 day moving average price is $6.95. The stock has a market capitalization of $742.21 million, a P/E ratio of -31.72 and a beta of 1.92. Gyre Therapeutics has a fifty-two week low of $5.44 and a fifty-two week high of $9.42.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GYRE. Geode Capital Management LLC increased its holdings in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after buying an additional 89,390 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after acquiring an additional 45,772 shares during the last quarter. Millennium Management LLC acquired a new position in Gyre Therapeutics in the third quarter valued at approximately $267,000. State Street Corp grew its position in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after acquiring an additional 19,472 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Gyre Therapeutics in the third quarter worth approximately $111,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on GYRE shares. Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research cut shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $16.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.